Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

« Older Entries
Newer Entries »

Could medical #marijuana help curb the #opioid crisis? #MMJ $N.ca $TBP.ca $MCOA

Posted by AGORACOM-JC at 5:10 PM on Tuesday, April 3rd, 2018
  • Medical marijuana could help quell the ongoing opioid epidemic, a pair of new studies contends.
  • Opioid prescriptions tend to decrease in U.S. states that adopt medical marijuana laws or legalize recreational use of pot, two different research teams have concluded.

The studies couldn’t prove cause and effect. But one study found that opioids dispensed through Medicare’s prescription drug plan decreased significantly if people had access to medical pot dispensaries or were allowed to grow marijuana for their own use.

“We had about a 14.5 percent reduction in opiate use when states turned on dispensaries, and about a 7 percent reduction in opiate use when states turned on home cultivation-based cannabis laws,” said researcher David Bradford, chairman of public policy at the University of Georgia School of Public and International Affairs.

The other study, led by researcher Hefei Wen, from the University of Kentucky College of Public Health, found a decrease in opioid prescriptions covered by Medicaid in states that legalized either medicinal or recreational pot.

Both types of laws were linked to about a 6 percent decline in opioid prescribing, researchers reported.

“We do think there’s good reason to be hopeful that cannabis might be one tool out of many we could use to address the opioid epidemic,” Bradford said.

Drug overdoses killed nearly 64,000 Americans in 2016, with two-thirds of deaths involving a prescription or illicit opioid, the U.S. Centers for Disease Control and Prevention reported last week. Overdose deaths rose 21.5 percent in 2016, a much sharper spike than the 11.4 percent increase seen the previous year.

At this point, 30 states and the District of Columbia have laws legalizing some form of marijuana use, including eight states that have legalized recreational use.

Studies have found medical pot is effective in treating chronic pain, Bradford said. In 2017, the prestigious National Academies of Sciences, Engineering and Medicine issued a report concluding that pot can significantly reduce pain symptoms.

Both research teams suspected that if this were true, then medical marijuana might ease opioid use in people with chronic pain.

To investigate this theory, the investigators turned to recent data from the federal insurance programs Medicare and Medicaid. They compared opioid prescribing patterns between states with medical or recreational pot and those that have taken a hard line against weed.

An average state filled 23 million daily doses of opioids through Medicare’s prescription drug plan between 2010 and 2015, Bradford’s team found.

But states with medical pot dispensaries filled 3.7 million fewer daily doses, and states with home cultivation filled 1.8 million fewer doses, they said.

Results did vary based on the type of opioid, however. Medical pot was linked to reductions in hydrocodone, morphine and fentanyl prescriptions, but not to prescriptions for oxycodone, Bradford said. The second study found a similar effect among people covered by Medicaid.

The two studies were published online April 2 in JAMA Internal Medicine.

“I think at this point, with patients dying every day as a result of opioid use disorder, we need to consider all possible solutions to the crisis,” said Dr. Kevin Hill, director of addiction psychiatry at Beth Israel Deaconess Medical Center in Boston and an assistant professor of psychiatry at Harvard Medical School. “Papers like these two suggest that cannabis may play a role.”

He said these studies and others offer strong support for anecdotal evidence from patients who report they need fewer opioids for chronic pain when they are put on medical cannabis. Hill wrote an editorial that accompanied the two articles.

At the same time, Hill says medical marijuana should not be given a lead role in treating chronic pain. Instead, it should be a back-up option for patients who are struggling to manage pain and who could be in danger of addiction.

“I think it’s hard to deny that there is a growing body of evidence that suggests a role for cannabis in treating chronic pain, but it’s not the level where it would be a first-line or even second-line treatment,” Hill said.

Source: https://www.cbsnews.com/news/could-medical-marijuana-help-curb-the-opioid-crisis/

Tags: , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Could medical #marijuana help curb the #opioid crisis? #MMJ $N.ca $TBP.ca $MCOA

Tetra Bio-Pharma $TBP.ca Names Guy Chamberland as Interim CEO $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:09 PM on Tuesday, April 3rd, 2018

Logo tetrabiopharma rgb web

  • Announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO)
  • Appointment is effective immediately

OTTAWA, ONTARIO–(April 3, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately.

Dr. Chamberland has been Chief Scientific Officer & Regulatory Affairs of Tetra since June 2016. He has over 23 years’ experience in the development of new drugs in the pharmaceutical industry (Canada and USA). He worked more than 10 years as an executive in various biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years.

Tetra’s former CEO, Bernard Fortier, left the corporation today thereby terminating his role as Chief Executive Officer and member of the Board of Directors.

“We are thankful for Bernard’s contributions to Tetra’s activities,” stated André Rancourt, Chairman of the Board. “Guy’s role as interim CEO will be a tremendous asset at this stage of Tetra’s growth. He will maintain his role and responsibility as Chief Scientific Officer while ensuring the growth and strategic operations of the corporation.”

Chamberland will serve as interim Chief Executive Officer while the Board of Directors conducts a search for a new Chief Executive Officer.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Names Guy Chamberland as Interim CEO $AERO $CBDS $CGRW $APH.ca $GBLX

5 things to know about #cannabis from Ontario’s latest provincial budget $N.ca $NXTTF $TBP.ca

Posted by AGORACOM-JC at 1:21 PM on Thursday, March 29th, 2018

Growing flowers of cannabis intended for the medical marijuana market are shown at OrganiGram in Moncton, N.B., on April 14, 2016. THE CANADIAN PRESS/Ron Ward

The Canadian Press
Published Wednesday, March 28, 2018 4:21PM EDT

TORONTO – As the federal government moves to legalize marijuana for recreational users later this year, Ontario’s latest budget sheds light on the province’s approach to sales, distribution, enforcement and revenue expectations.

– The Ontario Cannabis Retail Corporation, an LCBO subsidiary created to manage sales and distribution of recreational pot in the province, is not expecting to generate profits immediately after legalization. It is expecting an $8-million loss in 2017-2018, followed by a $40-million loss in 2018-19, largely due to initial startup costs to establish the retail network. By 2019-20, the province is forecasting OCRC net income of $35 million, followed by $100 million in net income by 2020-21.

– In a bid to crack down on the black market for marijuana in Ontario, the provincial government is creating a Cannabis Intelligence Co-ordination Centre to shut down illegal storefronts.

– The province will create a specialized legal team to support drug-impaired driving prosecutions. As well, it plans to fund sobriety field test training for police officers to help detect impaired drivers.

– Ontario will be providing municipalities with $40 million over the first two years of legalization to help with the costs of dealing with recreational pot. The Ontario Cannabis Legalization Implementation Fund will be funded by Ontario’s portion of the federal excise duty on recreational cannabis, at 75 per cent.

– Ontario plans to apply the full Harmonized Sales Tax, at 13 per cent, to off-reserve purchases of recreational cannabis by a Status Indian, band or band council, similar to tobacco and alcoholic beverages. However, medical cannabis purchased off-reserve from a licensed producer will be eligible for a rebate of the eight per cent provincial portion of the HST.

Source: https://www.cp24.com/news/5-things-to-know-about-cannabis-from-ontario-s-latest-provincial-budget-1.3863067

Tags: , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on 5 things to know about #cannabis from Ontario’s latest provincial budget $N.ca $NXTTF $TBP.ca

Namaste $N.ca $NXTTF Announces Appointment of Laurens Feenstra, Branden Spikes and Don Nickless to Board of Directors $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:59 AM on Wednesday, March 28th, 2018

Nlogo

  • Nominees and proposed board members have served in critical roles at Google, SpaceX and Seagram’s International
  • Bringing an intangible amount of value in helping advance the Company’s technology through innovation
  • Having individuals of this pedigree join Namaste at this point in the business cycle provides immediate legitimacy to the company and will help expedite Namaste’s plans to continue on the path of revolutionizing the cannabis industry

VANCOUVER, British Columbia, March 28, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that following the company’s Annual General Meeting of shareholders (“AGM”), which was held at the law offices of Gowling WLG (Canada) LLP on Tuesday, March 27, 2018, the Company has appointed Branden Spikes, Laurens Feenstra and Donald William Nickless (the “Board Appointees”) for positions on Namaste’s 2018 board of directors. The Board Appointees mark a pivotal milestone for Namaste in solidifying the board and supporting the Company’s future growth within the cannabis industry. The Nominees and proposed board members have served in critical roles at Google, SpaceX and Seagram’s International, and bring an intangible amount of value in helping advance the Company’s technology through innovation.

Namaste has been very selective in the appointment in these directors, as it looks to expand on its already impressive list of products and services. Each appointee brings an incredible amount of expertise in their respective discipline, and Namaste believes their experience will help further differentiate Namaste within the cannabis market, as an innovator in the space. Having individuals of this pedigree join Namaste at this point in the business cycle provides immediate legitimacy to the company and will help expedite Namaste’s plans to continue on the path of revolutionizing the cannabis industry.

The Nominees’ bios and experience are outlined below:

Laurens Feenstra – Laurens Feenstra is currently Product Manager at Waymo, formerly known as Google’s self-driving car project. Prior to Waymo, he worked on some of Google’s most well-known products such as Search, Chromebooks, and Android. As a strategy consultant at McKinsey & Company, he has helped large media, banking and government clients become data analytics-driven companies. Mr. Feenstra holds degrees in Human-Computer Interaction and Artificial Intelligence from University of Groningen in the Netherlands, and was a visiting researcher on “Intelligent Tutoring Systems” at Carnegie Mellon University. When not working on the latest technology, he organizes small electronic music festivals and runs a Burning Man camp.

Branden Spikes – Branden Spikes, considered as “Elon Musk’s most trusted lieutenant” by Venture Beat, worked side by side with Musk for over 15 years and helped pioneer ground breaking technologies at SpaceX, Tesla, and PayPal. He was the CIO of SpaceX for ten years and was instrumental in setting up the information systems at Tesla Motors during its formative years after having served as Director of IT at PayPal. Spikes then founded Spikes Security in 2012, with a mission to solve the most pressing cybersecurity challenge, browser malware and served as its CEO until it merged with Aurionpro in 2017. Mr. Spikes is an investor, advisor and a technology evangelist.

Donald William Nickless – Mr. Nickless graduated from Macdonald College of McGill University with a BSc in Agriculture. Mr. Nickless then worked for thirty plus years working for the Seagram Company Limited, beginning as a front-line supervisor in manufacturing, progressing through various Department Head positions to the manager of the Company’s largest Canadian plant. Subsequent, Mr. Nickless held various positions that culminated in the appointment to Executive Vice President of Manufacturing, Seagram Americas with responsibility for Manufacturing Operations in the US, Canada, and South America. Mr. Nickless is now retired and living in Vermont as a “Gentleman Farmer”.

In connection with these nominations, Peter Simeon and Philip van den Berg have stepped down from the Company’s board of directors.

We would also like to thank Peter Simeon and Philip van den Berg for serving on the Board.  Peter will continue to serve as legal counsel and corporate secretary to the Company and Philip will continue to serve as Chief Financial Officer.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments, “I’ve always believed that successful companies are the direct by-product of building exceptional teams. The appointment of Branden Spikes, Laurens Feenstra and Donald William are a testament to that belief, and I am extremely excited to have them join our team. These Nominees further strengthen our corporate structure as we continue to build the foundation of our company, as we look to create a unique identity in the cannabis space through innovation.  To date, Namaste has demonstrated its commitment to innovation through the adoption and implementation of many one-of-a-kind initiatives, and we fully intend on taking that philosophy to the next level with the addition of these highly experienced and well respected individuals.  As the cannabis market continues to evolve at a rapid pace, we are of the opinion that Namaste must continue to come up with inventive ways to appeal to cannabis patients on a global scale.   We believe collectively that these individuals  will help facilitate future growth opportunities  and help set Namaste apart  from others looking to capitalize on this exciting industry.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Tags: , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Appointment of Laurens Feenstra, Branden Spikes and Don Nickless to Board of Directors $ACB.ca $HIP.ca $WEED.ca $CMED.ca

#Marijuana stocks just got less risky, GMP Securities says $N.ca $NXTTF.ca $TBP.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:41 PM on Monday, March 26th, 2018

  • Recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities
  • Canada is poised to be an global leader in the cannabis space
  • This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana
  • bill passed 44 to 29

March 25, 2018 By Jayson MacLean

Canada’s still-developing cannabis sector has seen its share of fortunes won and lost over the past year, with stock prices skyrocketing in a matter of weeks over December and January, only to pull back considerably in the time since.

But recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities, who says Canada is poised to be an global leader in the cannabis space.

This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana. Although the vote was predicted to be tight, as some senators in favour of the legislation were out of Ottawa on committee work and Conservative senators promising to vote en masse against, the bill nevertheless passed 44 to 29.

That bodes well for the bill, says Landry, who projects a late summer/early fall opening up of the rec cannabis market.

“[The Senate vote] provides a positive read-through in our view for the potential outcome of the final third reading vote, as the majority of the Independent Senators Group appear to be aligned with the Liberals,” Landry said in a note to clients on Friday. “In a 3rd reading scenario where all Liberals and Conservatives vote for and against Bill C-45 respectively, this would suggest ~73 per cent of independents (versus 95 per cent at second reading) would need to vote in favour for Bill C-45 to become law.”

As well, this past week Health Canada released its fourth quarter 2017 data on medical marijuana use, finding that patient registrations were up 14 per cent on the quarter to 269,502, while total volume of medical cannabis grew around 10 percent on the quarter and around 34 per cent year-over-year, the best growth rate over the past three quarters, says Landry.

Also coming from Health Canada were summary results from public consultations on the new cannabis regulations, held during a 60-day period starting this past November. The consultations drew in approximately 4,000 responses, covering all aspects of the proposed regulations including licensing and permits, security clearance and cannabis tracking, product packaging and labelling and the medical use of cannabis.

Some notable results include strong support from respondents for a quick roll-out on regulations regarding cannabis edibles along with majority support for the government’s plans concerning licensing and product labelling and plain packaging.

Landry says that going forward the report should feed into guidance and regulations for industry participants. On the issue of product labelling, the analyst says that Health Canada’s push for plain packaging could make it “difficult for licensed producers to differentiate their brands on the basis of packaging, however advertising rules are not expected to be more restrictive than those for tobacco,” Landry says.

In all, Landry sees the ramped up medical market and the maturing regulatory landscape to be a win for Canadian companies, who now have a head start over the competition when it comes to the industrial production of cannabis within a tightly regulated environment.

Landry says that having LPs required to deliver secure and stable production has “led Canadian licensed producers to build pharmaceutical grade production facilities, develop solid cultivation know-how and create a large bank of genetics,” he says. “Combined with well capitalized balance sheets, we believe that Canadian LPs are well positioned to become global leaders in the cannabis sector.”

Source: https://www.cantechletter.com/2018/03/marijuana-stocks-just-got-less-risky-gmp-securities-says/

Tags: , , , , ,
Posted in All Recent Posts, Featured, Marijuana Company of America, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on #Marijuana stocks just got less risky, GMP Securities says $N.ca $NXTTF.ca $TBP.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca $NXTTF Announces Non-Binding Terms Sheet With Australian-Based Medical Cannabis Company PharmaCann Pty Ltd $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:39 AM on Thursday, March 22nd, 2018

Nlogo

  • Signed a non-binding Terms Sheet with PharmaCann Pty Ltd.
  • Namaste will participate in an investment to purchase a 10% equity position in PharmaCann
  • PharmaCann currently operates with existing licenses to import, export and wholesale medical cannabis issued by the Australian Government Department of Health

VANCOUVER, British Columbia, March 22, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ)(OTCMKTS:NXTTF) is pleased to announce that it has signed a non-binding Terms Sheet (the “Terms Sheet”) with PharmaCann Pty Ltd. (“PharmaCann”), whereby Namaste will participate in an investment to purchase a 10% equity position in PharmaCann. PharmaCann currently operates with existing licenses to import, export and wholesale medical cannabis issued by the Australian Government Department of Health. Namaste’s investment in PharmaCann will be used by PharmaCann to proceed with its application to further secure a cultivation license. The Australian market represents a major component of Namaste’s current revenue, which is derived in hardware sales, and remains a primary focus of Namaste’s strategic initiatives as it looks to target the Australian medical cannabis industry. Namaste believes PharmaCann’s import, export and wholesale licenses bring immediate value to the Company and believes that  PharmaCann has the ability to obtain a cultivation license which will further enhance Namaste’s ability to penetrate global markets. In addition to Namaste’s strategic investment in PharmaCann, the Terms Sheet outlines additional business ventures between both parties as outlined below.

 

Key Terms:

  • Namaste will provide a cash investment for 10% equity in PharmaCann.
  • Namaste will purchase 250kg annually of medical cannabis for export to Canada under the Company’s wholly owned subsidiary Cannmart Inc. (“Cannmart”) for the next three years, subject to approval by Health Canada.
  • Namaste will assist PharmaCann with implementation of a global distribution strategy.
  • Namaste will provide non-exclusive access to its database of Australian consumers.
  • PharmaCann will leverage its import, export and wholesale licenses to support Namaste in international markets.
  • PharmaCann will grant up to 10% of its useable space to develop genetic strains of medical cannabis with Namaste.
  • PharmaCann will perform clinical trials with the use of Namaste’s hardware and client-base, in accordance with Australian state and federal laws.
  • Closing of the proposed agreement will be contingent upon negotiating and execution of definitive documentation and approval of the terms of the agreement by each party’s respective directors.

Namaste remains committed to focusing on opportunities and collaborations with PharmaCann in the Australian market, as it represents an important part of the Company’s growth strategy moving forward. As the Canadian market progresses closer towards full legalization, Namaste is of the opinion that additional markets, such as Australia, will provide Namaste with a more diverse market presence by allowing the Company to continue leveraging its global database of cannabis users. This strategy represents an opportunity for Namaste to expand its global ecommerce platform into other progressive markets, as it looks to replicate the success it has achieved in the Canadian market.

Management Commentary

Victor Caprio, Managing Director and CEO of PharmaCann comments: “PharmaCann is excited to be working with Namaste to strengthen our respective positions in the Australian and International Markets. With Namaste’s strategic investment in PharmaCann, we strongly believe that our current foothold in the Australian Market will be amplified exponentially and will provide us with further opportunities to increase our market offerings, whilst allowing for further growth in this exciting and ever-evolving industry. Additionally, our teams look forward to continuing our close working relationship together to ensure that our shared values and overall objectives are maintained, both now and into the future.”

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to announce this non-binding Terms Sheet with PharmaCann. This is something we have been working on for several months and having received our Canadian ACMPR license, we plan on executing our strategy to launch a similar platform in regional markets where Namaste maintains large market presence. There are a multitude of synergistic relationships with PharmaCann not only from cultivation but in leveraging PharmaCann’s import, export and wholesale licenses to expand on our global operations. We are very excited at the incredible opportunities that exist globally, as other countries look to capitalize on the rapidly growing cannabis industry.”

About PharmaCann

PharmaCann Pty Ltd is an Australian Company that was formed by a group of entrepreneurs, whom shared the same belief that medicinal cannabis can be a beneficial and viable treatment option for patients with multiple and varying conditions throughout Australia and the world. PharmaCann formed its Biotechnology and Nutraceutical Company with a team of public health and medical experts dedicated and committed to supplying an alternative to traditional medications with the use of cannabinoids. Our Medical and Allied Health Network works diligently to ensure that Patients have adequate access to alternative treatment options, whilst working closely with our State and Federal Regulatory Agencies to ensure that adequate access is maintained.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

PharmaCann Pty Ltd
“Victor Caprio”
Managing Director & CEO
Email: [email protected]

 

Further information on the Company and its products can be accessed through the links below:

 

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca
Pharmacann.com.au

 

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Non-Binding Terms Sheet With Australian-Based Medical Cannabis Company PharmaCann Pty Ltd $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca Announces Medical Cannabis Supply Agreement With Leading Jamaican Producer Marigold $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 10:13 AM on Tuesday, March 20th, 2018

Nlogo

  • Announced that it has signed a Medical Cannabis Supply Agreement with Marigold Projects Jamaica 
  • Marigold will supply Cannmart with high quality Jamaican produced medical cannabis, to be imported by Cannmart from Jamaica and offered in the Company’s online marketplace, subject to approval by Health Canada and the Cannabis Licencing Authority

VANCOUVER, British Columbia, March 20, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has signed a Medical Cannabis Supply Agreement (the “Supply Agreement”) with Marigold Projects Jamaica Ltd. (“Marigold”) under its wholly owned subsidiary, Cannmart Inc. (“Cannmart”), whereby Marigold will supply Cannmart with high quality Jamaican produced medical cannabis, to be imported by Cannmart from Jamaica and offered in the Company’s online marketplace, subject to approval by Health Canada and the Cannabis Licencing Authority. This Supply Agreement further supports Namaste’s vision of creating a diverse platform for medical patients to access high quality cannabis, sourced from both domestic and international producers.

Key Terms of the Supply Agreement:

  • Cannmart will submit purchase orders to Marigold for medical cannabis.
  • Cannmart will import medical cannabis from Marigold, subject to approval by Health Canada.
  • Cannmart will be compliant with Marigold’s branding and pricing strategy.
  • Cannmart will be responsible for shipping and importation costs of the product.
  • Marigold will provide Cannmart with lab test reports for each purchase in advance and in accordance with Cannmart’s requirements under Canadian regulations.
  • Packaging of products will bear the Marigold brand logo.

The Supply Agreement with Marigold exemplifies a major component of Namaste’s strategy in providing Canadian patients with access to high-quality imported medical cannabis. Marigold’s strong management team and extensive experience in cultivation will add significant value to Cannmart’s product offering. The Company anticipates strong demand for imported medical cannabis products and looks forward to further developing a relationship with Marigold and its management team.

Management Commentary

Clifford Starke, Chairman of Marigold comments: “Sean and his team have created a leading global web platform in the cannabis accessories industry. Now with an ACMPR production license in hand and the release of the NamasteMD app, we expect Namaste to further disrupt the cannabis industry using their innovative approach to product marketing. As Marigold enters its growth phase, weeks away from first commercial harvest, we look forward to becoming a trusted supplier of premium medicinal cannabis products to Namaste’s customer base. We are thrilled to work with Namaste and look forward to further developing this strategic partnership in step with the legalization of medical cannabis worldwide.”

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to announce this Supply Agreement with Marigold as we look to expand our product offering through Cannmart. The importation of medical cannabis will serve as a strong niche for Namaste in the Canadian marketplace. We believe this strategy will help set Namaste apart from its competitors.  Although Cannmart’s patients will have access to some of the highest quality medical cannabis sourced from domestic licensed producers, we feel that there is major value in providing our patients with premium quality imported products as well. We thank Marigold’s management team for working with us to prepare the Supply Agreement and we anticipate a long-term mutually beneficial relationship with them. Having recently received our ACMPR medical cannabis production license for Cannmart, we’re looking forward to exploring new opportunities in this exciting industry.”

About Marigold

Marigold is a vertically integrated cannabis company located in Jamaica with over 70 acres in the Sunshine City and the famous Blue Mountains. Led by a High Times Hall of Fame breeder and 19-time Cannabis cup winner, current operations include 10-acres of outdoor production with the first commercial harvest underway. Marigold is rapidly building out its product suite utilizing top technology hydroponic greenhouses and nurturing specialized strains unique to Jamaica’s climate as well as developing the tourist and local market via dispensaries and herb shops. With one of the only research and development licenses in the country and an exclusive partnership with the University of West Indies, Marigold intends to leverage its low cost, scalable cultivation operations along with world-class portfolio of strains and cultivation expertise to provide markets across the world with a high volume of premium, cost effective cannabis products.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

 

Tags: , ,
Posted in Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces Medical Cannabis Supply Agreement With Leading Jamaican Producer Marigold $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca Added to Leading #Cannabis ETF: Horizons Marijuana Life Sciences Index $HMMJ.ca

Posted by AGORACOM-JC at 8:23 AM on Tuesday, March 20th, 2018

Logo tetrabiopharma rgb web

  • Announced that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.
  • HMMJ was the first and is the world’s largest ETF offering direct exposure to North American-listed securities that are involved with marijuana bioengineering and production

OTTAWA, ONTARIO–(March 20, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.

HMMJ was the first and is the world’s largest ETF offering direct exposure to North American-listed securities that are involved with marijuana bioengineering and production. The HMMJ portfolio recently expanded to include ten new constituents, including Tetra.

“This is a very positive sign for our shareholders,” says Bernard Fortier, CEO of Tetra. “Having Horizons trusting us after completing a $11.5 million bought deal and in the process of a $ 4.5 million private placement is a strong message of confidence. Our clinical approach and pipe-line of products are unique and being added to this index reinforces the credibility of our approach to the financial community.”

HMMJ is an index (or passively managed) ETF, which seeks to replicate, to the extent possible, the performance of the North American Marijuana Index (the “Index”), net of expenses. The Index is designed to provide exposure to the performance of a basket of North American publicly listed life sciences companies with significant business activities in the marijuana industry. The Index selects from a current universe of companies that have operations that may include one or more of biopharmaceuticals, medical manufacturing, distribution, bio-products and other ancillary businesses related to the marijuana industry.

More info on: https://www.horizonsetfs.com/news/Press-Release/Horizons-ETFs-Completes-Rebalance-of-its-Marijuana

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Added to Leading #Cannabis ETF: Horizons Marijuana Life Sciences Index $HMMJ.ca

REPEAT: Namaste $N.ca $NXTTF Receives ACMPR Medical #Cannabis Production License $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:52 AM on Monday, March 19th, 2018

Nlogo

  • Wholly owned subsidiary, Cannmart has received its Access to Cannabis for Medical Purposes Regulations Production License
  • Cannmart may now place initial orders with ACMPR licensed producers
  • Confident in its ability to execute and complete the final steps towards receiving its Sales License in a timely manner
  • With receipt of the production license, Namaste now expects to execute on its overall vision of becoming an all-inclusive online cannabis marketplace

VANCOUVER, British Columbia, March 16, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that its wholly owned subsidiary, Cannmart Inc. (“Cannmart”) has received its Access to Cannabis for Medical Purposes Regulations (“ACMPR”) Production License (the “License”). Under the guidelines set forth by Health Canada, Cannmart may now place initial orders with ACMPR licensed producers. Upon receipt, packaging and testing of the initial shipments of medical cannabis, the Company is then required to demonstrate compliance with standard operating procedures (“SOPs”) and other ACMPR regulatory requirements with Health Canada. Once these objectives have been achieved and following an initial inspection, Cannmart will be able to book a Pre-Sales License Inspection after which the Company will be eligible to receive its ACMPR Sales License. Cannmart believes it is well prepared and confident in its ability to execute and complete the final steps towards receiving its Sales License in a timely manner.

If Cannmart receives its Sales License, Cannmart will then operate as one of the first aggregators of medical cannabis, sourced from handpicked ACMPR licensed producers. The Company has identified the need for a competitive landscape where patients have the ability to access a larger variety of medical cannabis strains and oils, without the need to change licensed producers. Through a combination of strategic service and supply agreements, Cannmart will be well-positioned to provide Canadian patients with access to a wide range of medical cannabis products through the most diverse online platform in the Canadian cannabis market. Namaste acquired Cannmart as a late-stage ACMPR applicant, with the intention of creating Canada’s most expansive marketplace for medical cannabis. The receipt of the Production License represents a significant milestone for the Company and will help to propel Namaste to become one of Canada’s leading e-commerce retailer of medical cannabis.

Namaste currently operates one of the largest global e-commerce platforms for cannabis delivery devices and plans to leverage its technology and consumer data with the end goal of acquiring medical patients. In order to facilitate growth at an accelerated rate, the Company plans to utilize its recently launched mobile application under its wholly owned subsidiary, NamasteMD Inc. (“NamasteMD”). This revolutionary medical cannabis app is Canada’s first virtual patient consultation portal to be approved by Apple and Google to be used on both iOS and Android devices. NamasteMD will serve the company as a patient acquisition tool, allowing patients to connect with doctors and nurse practitioners in a safe and secure online environment from the comfort of their homes. NamasteMD was designed to streamline the patient onboarding process in comparison to traditional brick-and-mortar clinics.

With receipt of the production license, Namaste now expects to execute on its overall vision of becoming an all-inclusive online cannabis marketplace and creating a platform that consolidates many of the best product offerings by the top ACMPR Licensed Producers in Canada. Namaste believes it can now deliver on its promise of providing patients with a true “one stop shopping” experience. Namaste will continue creating strategic partnerships through various agreements in attempt to innovate in the Canadian medical cannabis industry.

Further to this news release, Namaste will host a special edition Namaste Live420 on the Company’s YouTube channel via the link below, on Monday, March 19th, 2018 at 8:30 AM EDT to discuss and answer shareholder questions.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “This important milestone represents an incredible achievement for Namaste and its shareholders. Receipt of the ACMPR Production License not only validates Namaste’s strategy but it serves as a critical component of the Company’s anticipated growth moving forward.  We are very proud to have met our goal of receiving our ACMPR medical cannabis Production License from Health Canada as we look to explore the tremendous opportunities that exist in the Canadian cannabis market. While we are excited with this achievement, management remains highly focused on completing the final protocols set forth by Health Canada and plan on executing the final steps towards receiving our “Sales Only” License.  If the Sales Licence is received, we fully intend on leveraging our data and technology through our global network of operations where we believe we will be well-positioned to implement the same strategy in other legal markets where the Company has established strong market share.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to cr

Tags: , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on REPEAT: Namaste $N.ca $NXTTF Receives ACMPR Medical #Cannabis Production License $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:13 AM on Monday, March 19th, 2018

Logo tetrabiopharma rgb web

  • Announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary
  • Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders

OTTAWA, ONTARIO–(March 19, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the “Transaction“) from entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Sellers“).

“The Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO. “It allows Tetra to gain 100% control of PhytoPain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives Tetra full flexibility to enter into other partnerships or agreements in the future.”

The purchase price for the Transaction was comprised of a combination of cash, promissory notes and common shares of Tetra, some of which will be released to the Sellers upon the achievement of key milestones. The terms of the Transaction are detailed in the Corporation’s news release dated January 2, 2018 which is available on SEDAR under the Corporation’s profile. The Corporation used $500,000 out of the proceeds from the recently completed bought deal offering to repay a portion of the principal amount owing to the Sellers under the promissory notes.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

« Older Entries
Newer Entries »